Overview

Tau PET Outcomes With Anti-amyloid Immunotherapies

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Phase:
PHASE2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole